Gavi recruiting consultant positions for its next Vaccine Investment Strategy (VIS)
Gavi is currently recruiting three consultant positions to support Gavi’s next Vaccine Investment Strategy (VIS). The VIS is Gavi’s evidence-informed process that takes place every 5 years to evaluate the full value of new vaccines (or underused ones) in support of Gavi’s Board investment decisions. Selected vaccines would then be included into Gavi’s portfolio at the next strategic period (2026-2030). The consultant roles are one-year roles with possibility of extension. Candidates are sought with experience in public health, epidemiology, health economics, impact modelling or closely related field and with strong quantitative and qualitative analysis skills. In particular, the consultant positions are a great opportunity for researchers with an interest in policy analysis and investment case development to get exposure to how policy and investment decisions are made, including engagement with numerous stakeholders.
The following consultants are being recruited:
1 x Senior manager (L4)
2 x Data analyst (L2)
EDCTP Fellows in the times of COVID-19
Our EDCTP Fellows have been very active across the continent in the response to the COVID-19 pandemic. Many countries around the world have been in varying degrees of lockdown and have relied heavily on advice from medical specialists, epidemiologists and researchers to guide their response. Please read our EDCTP monthly updates as we showcase the work of our Fellows each month https://www.edctp.org/web/app/uploads/2020/08/EDCTP-Update-July-2020.pdf
Bourema Kouriba - COVID-19 diagnosis in Mali
Professor Bourema Kouriba (a former EDCTP1 senior Fellow) is a pharmacist, immunologist, and the Director General of the Charles Mérieux Centre for Infectiology (CMCI) in Bamako, Mali. He leads a team responsible for diagnostics of emerging and re-emerging infectious diseases and teaches immunology at the Faculties of Medicine and Pharmacy in Bamako.
Since the Ebola epidemic in 2014, the institute developed its diagnostics capabilities with the support of the Institute of Microbiology of the German Army. The German government donated a mobile laboratory to the Malian Ministry of Health under the responsibility of CMCI, which participates with the National Institute of Public Health in epidemiological surveillance and the response to epidemics. Professor Kouriba: "On the outbreak of the COVID-19 pandemic in March 2020, CMCI and three other
centres were appointed by the Ministry of Health and Social Affairs to carry out the diagnostic side. Right now, we are in Timbuktu, a town in the north at 900 km from the capital Bamako. Here, our mobile laboratory is deployed to carry out the COVID19 molecular diagnostic tests. The day begins with the preparation of bleach solutions. Then we organise the team in the different workstations: one person at the reception, two people in the glove box, one person at the RNA extraction and the preparation of the master mix and another at the amplification."
"I take care of entering data and editing the results personally. As soon as the samples are received, their number is counted and communicated to the entire team. Once received, samples are conditioned in a container and transferred to the glove box team whose role is to inactivate these samples. This inactivation is carried out under the control of a witness who notes on the patient form all the steps performed by the operator. After inactivation, the samples are removed from the glove box for RNA extraction. At the same time, one person responsible for preparing the master mix prepares the necessary quantity of reagent. The last step is the real-time PCR. After two hours the results are analysed, interpreted, entered into the
database and printed for the doctor. At the end of the day, the glove compartment and the equipment are cleaned with concentrated bleach." There are several serious challenges:
1. The situation of consumables used for PCR, in particular for extraction kits. With the borders closed, the supply of reagents and consumables in the country is a very big challenge.
2. We receive most of our reagents through donors as the government cannot afford to buy them. Each donor buys reagents, which poses a problem for having a uniform algorithm to interpret the results.
3. Non-compliance with distancing and prevention measures which increases the number of contact cases, hence the number of samples to be tested per day. The laboratory works at least 10 hours a day to meet demand.
"We are in an unprecedented pandemic against which we are actually learning and responding at the same time. Timbuktu is in the north in an insecure area of Mali and the temperature fluctuates between 42 and 46 degrees Celsius. But it is our population and we must guarantee equity in access to care. Everyone should take this pandemic seriously and show solidarity with countries with limited resources because SARS-COV2 does not know borders and does not differentiate between people. Countries must be united in the fight against COVID-19."
Carnegie African Diaspora Fellowship Program - transforming the continent's brain drain into brain circulation!
Acredited universities in Ghana, Kenya, Nigeria, South Africa, Tanzania and Uganda can submit a project request online to host a scholar. African host institutions can request that the scholar participate in projects in curriculum co-development, collaborative research and/or graduate student teaching and mentoring. Links to the African host institution project request application, scholar roster application and guidelines are posted on the CADFP website (https://www.iie.org/Programs/Carnegie-African-Diaspora-Fellowship-Program/How-to-Apply/For-African-Institutions).
Selection decisions will be made in April 2019; project visits can begin as early as May 2019 and must be completed by August 31, 2019.
Call for applications: Michelson Prizes Next Generation Grants | Deadline: 11 June 2023
Michelson Prizes Next Generation Grants are annual awards of $150,000, which support early-career investigators (35 years and under) who are working to significantly advance human immunology and vaccine and immunotherapy research for major global diseases. The research to be covered by the grant should aim at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development. The Prizes are awarded by the Michelson Medical Research Foundation and the Human Immunome Project (formerly the Human Vaccines Project). Applications are being accepted with a deadline of 11 June 2023.
More information www.humanimmunomeproject.org/michelsonprizes